Treatment News : Clinical Trial of Triple-Drug Combination Pill 572-Trii Begins

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 3, 2011

Clinical Trial of Triple-Drug Combination Pill 572-Trii Begins

ViiV Healthcare and Shionogi & Co. announced Thursday, February 3, that the first patient has been enrolled into a study exploring the safety and efficacy of 572-Trii, the companies’ fixed-dose combination pill containing the experimental integrase inhibitor S/GSK1349572 (S/GSK-572) and Epzicom (lamivudine plus abacavir). 

“We are seeking to create an integrase-based, once-daily fixed-dose combination that helps meet patient needs,” says Dominique Limet, ViiV Healthcare’s chief executive officer. “We know that even with the successes of current therapies, patients still need additional treatment options, and we will continue to evaluate existing and pipeline compounds for new combination therapies.”

The international clinical trial, dubbed SINGLE, is a randomized and blinded two-arm study comparing once-daily 572-Trii with once-daily Atripla (efavirenz plus tenofovir and emtricitabine). The study will include about 800 people living with HIV who are starting antiretroviral therapy for the first time. 

The primary objective for the SINGLE study will be to demonstrate the antiviral activity of 572-Trii, compared with Atripla, over 48 weeks. Secondary objectives include the assessment of the tolerability, long-term safety and antiviral and immunologic activity of 572-Trii once-daily, compared with Atripla, over 96 weeks. Investigators will also evaluate viral resistance in patients experiencing virologic failure.

To learn more about the study and enrollment sites, including one in Wilton Manors, Florida, click here.

Search: S/GSK1349572, S/GSK-572, 572, 572-Trii, ViiV Healthcare, Shionogi, Atripla, clinical trial, integrase inhibitor


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    Sin_Grinder
    Reno
    Nevada


    jimmy807
    San Antonio
    Texas


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.